Sandler Capital Management Acquires 6,605 Shares of Boston Scientific Corporation $BSX

Key Points

• Sandler Capital Management has increased its stake in Boston Scientific Corporation by 18.8%, now holding a total of 41,782 shares, valued at approximately $4.2 million.
• Corporate insiders, including an executive vice president and a director, have recently sold 54,000 shares of Boston Scientific, indicating a decrease in their ownership of the stock.
• Boston Scientific reported strong earnings with a $0.75 earnings per share, exceeding analyst expectations and reflecting a 22.8% year-over-year revenue increase.

Sandler Capital Management grew its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 18.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 41,782 shares of the medical equipment provider's stock after purchasing an additional 6,605 shares during the quarter. Boston Scientific makes up approximately 1.1% of Sandler Capital Management's holdings, making the stock its 29th biggest holding. Sandler Capital Management's holdings in Boston Scientific were worth $4,215,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BSX. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG raised its holdings in Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares during the period. Highview Capital Management LLC DE raised its holdings in Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after buying an additional 1,439 shares during the period. Algert Global LLC acquired a new stake in Boston Scientific during the 4th quarter worth approximately $297,000. Finally, Captrust Financial Advisors raised its holdings in Boston Scientific by 18.0% during the 4th quarter. Captrust Financial Advisors now owns 54,580 shares of the medical equipment provider's stock worth $4,875,000 after buying an additional 8,316 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 in the last ninety days. Corporate insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on BSX shares. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Oppenheimer raised their target price on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a report on Thursday, July 24th. Wells Fargo & Company raised their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Robert W. Baird lifted their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Price Performance

NYSE BSX opened at $107.14 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $108.94. The company has a market capitalization of $158.76 billion, a PE ratio of 63.78, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. The firm's 50 day moving average is $104.77 and its 200-day moving average is $102.20.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue was up 22.8% on a year-over-year basis. During the same period last year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.